Base de dados : MEDLINE
Pesquisa : D08.811.277.656.300.480.205.500 [Categoria DeCS]
Referências encontradas : 5423 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 543 ir para página                         

  1 / 5423 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29305454
[Au] Autor:Sanjuan-Cerveró R; Carrera-Hueso FJ; Vazquez-Ferreiro P; Ramon-Barrios MA
[Ad] Endereço:Department of Orthopedics and Traumatology Surgery, Hospital de Denia , Partida Beniadlà, S/N, Dénia, Alicante 03700, Spain and Doctor of Pharmacy Programme, University of Granada, Granada, Spain.
[Ti] Título:Efficacy and adverse effects of collagenase use in the treatment of Dupuytren's disease: a meta-analysis.
[So] Source:Bone Joint J;100-B(1):73-80, 2018 Jan.
[Is] ISSN:2049-4408
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: The aim of this meta-analysis was to assess the safety and efficacy of collagenase clostridium histolyticum compared with fasciectomy and percutaneous needle fasciotomy (PNF) for Dupuytren's disease. MATERIALS AND METHODS: We systematically searched PubMed, EMBASE, LILACS, Web of Science, Cochrane, Teseo and the ClinicalTrials.gov registry for clinical trials and cohort or case-control studies which compared the clinical outcomes and adverse effects of collagenase with those of fasciectomy or PNF. Of 1345 articles retrieved, ten were selected. They described the outcomes of 425 patients treated with collagenase and 418 treated by fasciectomy or PNF. Complications were assessed using inverse-variance weighted odds ratios (ORs). Clinical efficacy was assessed by differences between the means for movement of the joint before and after treatment. Dose adjustment was applied in all cases. RESULTS: Random-effects modelling showed that patients treated with collagenase had 3.24 increased odds of adverse effects compared with those treated by fasciectomy (OR 4.39) or PNF (OR 1.72,). The effect was lost when only major complications were assessed. Joint movement analysis revealed a difference between means of less than 10%, indicating equivalent clinical efficacy in the short and medium term for collagenase and fasciectomy. We were unable to analyse this for PNF due to a shortage of data. CONCLUSION: There were no significant differences in effect size between collagenase and fasciectomy. The use of collagenase was associated with a higher overall risk of adverse effects than both fasciectomy and PNF. Cite this article: 2018;100-B:73-80.
[Mh] Termos MeSH primário: Contratura de Dupuytren/tratamento farmacológico
Colagenase Microbiana/uso terapêutico
[Mh] Termos MeSH secundário: Contratura de Dupuytren/cirurgia
Fasciotomia/efeitos adversos
Fasciotomia/métodos
Seres Humanos
Injeções Intralesionais
Colagenase Microbiana/administração & dosagem
Colagenase Microbiana/efeitos adversos
Procedimentos Cirúrgicos Minimamente Invasivos/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180107
[St] Status:MEDLINE
[do] DOI:10.1302/0301-620X.100B1.BJJ-2017-0463.R1


  2 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28612401
[Au] Autor:Abdel Raheem A; Capece M; Kalejaiye O; Abdel-Raheem T; Falcone M; Johnson M; Ralph OG; Garaffa G; Christopher AN; Ralph DJ
[Ad] Endereço:Andrology Department, University College London Hospital and The Institute of Urology London and St Peter's Andrology Centre, London, UK.
[Ti] Título:Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
[So] Source:BJU Int;120(5):717-723, 2017 Nov.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the efficacy and safety of collagenase clostridium histolyticum (CCH; Xiapex , Xiaflex ) in the treatment of Peyronie's disease (PD) using a new modified treatment protocol that aims at reducing the number of injections needed and reducing patient visits, thus reducing the duration and cost of treatment. PATIENTS AND METHODS: A prospective study of 53 patients with PD who had treatment with CCH at a single centre using a new modified protocol. The angle of curvature assessment after an intracavernosal injection of prostaglandin E1, the International Index of Erectile Function (IIEF) and Peyronie's Disease Questionnaire (PDQ) were completed at baseline and at week 12 (4 weeks after the last injection). The Global Assessment of Peyronie's disease (GAPD) questionnaire was completed at week 12. Under a penile block of 10 mL plain lignocaine 1%, a total of three intralesional injections of CCH (0.9 mg) were given at 4-weekly intervals using a new modified injection technique. In between injections patients used a combination of home modelling, stretching and a vacuum device on a daily basis to mechanically stretch the plaque. Investigator modelling was not performed. RESULTS: The mean (range) penile curvature at baseline was 54 (30-90)°. Of the 53 patients in the study, 51 patients (96.2%) had an improvement in the angel of curvature by a mean (range) of 17.36 (0-40)° or 31.4 (0-57)% from baseline after three CCH injections. The final mean (range) curvature was 36.9 (12-75)° (P < 0.001). There was an improvement in each of the IIEF questionnaire domains, all three PDQ domains and the GAPD. CCH was well tolerated by all patients with only mild and transient local adverse events. CONCLUSION: The new shortened protocol using CCH treatment is safe, effective, and cost efficient. The results of using only three CCH injections according to this modified protocol are comparable to those of the clinical trials that used eight CCH injections.
[Mh] Termos MeSH primário: Colagenase Microbiana/uso terapêutico
Induração Peniana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Seres Humanos
Injeções Intralesionais
Masculino
Colagenase Microbiana/administração & dosagem
Meia-Idade
Induração Peniana/fisiopatologia
Pênis/fisiopatologia
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13932


  3 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28181175
[Au] Autor:Sanjuan-Cerveró R; Carrera-Hueso FJ; Vazquez-Ferreiro P; Gomez-Herrero D
[Ad] Endereço:Orthopedics and Traumatology Surgery, Hospital de Denia, Partida Beniadlà, S/N, Denia, 03700, Alicante, Spain. sanjuan.rafcer@gmail.com.
[Ti] Título:Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review.
[So] Source:BioDrugs;31(2):105-115, 2017 Apr.
[Is] ISSN:1179-190X
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Collagenase clostridium histolyticum (CCH) has proven to be both safe and effective in the treatment of Dupuytren disease (DD). The medium-term outcomes are similar to those achieved with surgery, and most adverse effects are self-limiting and considered to be mild or moderate. OBJECTIVE: Our objective was to conduct a systematic review of the adverse effects of CCH in DD since the release of the drug to evaluate the incidence, severity, classification, and definitions of these effects. METHODS: We analyzed the literature in terms of modifications to the original treatment protocol and grouped adverse effects according to their pathophysiological origin. RESULTS: We included 28 clinical studies and five case reports or case series analyzing 4456 patients with a mean age of 63.6 years. Mean follow-up was 7.07 months (range 3-24); the mean number of patients per study was 148 (range 5-1082). The studies did not classify the adverse effects they reported into groups. The most common effects were peripheral edema (54.4%), bruising (42.9%), and upper limb pain (28.3%). Significant biases were observed for use of terminology, demarcation of sites of involvement, severity criteria, and assessment methods. CONCLUSION: A simpler and clearer consensus-based classification system would enable better evaluation and comparison of the adverse effects of CCH in the treatment of DD. Consideration of inflammatory phenomena as part of the drug's mechanism of action would significantly reduce overall rates of adverse effects.
[Mh] Termos MeSH primário: Contratura de Dupuytren/tratamento farmacológico
Colagenase Microbiana/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Terminologia como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.1007/s40259-017-0211-z


  4 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28002244
[Au] Autor:Shubinets V; Lin IC; Chang B
[Ad] Endereço:Division of Plastic Surgery, University of Pennsylvania Health System, Philadelphia, Pa.
[Ti] Título:Carpal Tunnel Syndrome after Xiaflex Injection for Dupuytren Disease.
[So] Source:Plast Reconstr Surg;139(4):1031e-1032e, 2017 04.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome do Túnel Carpal/induzido quimicamente
Contratura de Dupuytren/tratamento farmacológico
Colagenase Microbiana/efeitos adversos
[Mh] Termos MeSH secundário: Clostridium histolyticum
Dedos
Seres Humanos
Injeções Intralesionais
Masculino
Meia-Idade
Amplitude de Movimento Articular/fisiologia
Recidiva
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003163


  5 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27821608
[Au] Autor:Obana N; Nakamura K; Nomura N
[Ad] Endereço:Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan obana.nozomu.gb@u.tsukuba.ac.jp.
[Ti] Título:Role of RNase Y in Clostridium perfringens mRNA Decay and Processing.
[So] Source:J Bacteriol;199(2), 2017 Jan 15.
[Is] ISSN:1098-5530
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RNase Y is a major endoribonuclease that plays a crucial role in mRNA degradation and processing. We study the role of RNase Y in the Gram-positive anaerobic pathogen Clostridium perfringens, which until now has not been well understood. Our study implies an important role for RNase Y-mediated RNA degradation and processing in virulence gene expression and the physiological development of the organism. We began by constructing an RNase Y conditional knockdown strain in order to observe the importance of RNase Y on growth and virulence. Our resulting transcriptome analysis shows that RNase Y affects the expression of many genes, including toxin-producing genes. We provide data to show that RNase Y depletion repressed several toxin genes in C. perfringens and involved the virR-virS two-component system. We also observe evidence that RNase Y is indispensable for processing and stabilizing the transcripts of colA (encoding a major toxin collagenase) and pilA2 (encoding a major pilin component of the type IV pili). Posttranscriptional regulation of colA is known to be mediated by cleavage in the 5' untranslated region (5'UTR), and we observe that RNase Y depletion diminishes colA 5'UTR processing. We show that RNase Y is also involved in the posttranscriptional stabilization of pilA2 mRNA, which is thought to be important for host cell adherence and biofilm formation. IMPORTANCE: RNases have important roles in RNA degradation and turnover in all organisms. C. perfringens is a Gram-positive anaerobic spore-forming bacterial pathogen that produces numerous extracellular enzymes and toxins, and it is linked to digestive disorders and disease. A highly conserved endoribonuclease, RNase Y, affects the expression of hundreds of genes, including toxin genes, and studying these effects is useful for understanding C. perfringens specifically and RNases generally. Moreover, RNase Y is involved in processing specific transcripts, and we observed that this processing in C. perfringens results in the stabilization of mRNAs encoding a toxin and bacterial extracellular apparatus pili. Our study shows that RNase activity is associated with gene expression, helping to determine the growth, proliferation, and virulence of C. perfringens.
[Mh] Termos MeSH primário: Clostridium perfringens/enzimologia
Regulação Bacteriana da Expressão Gênica/fisiologia
RNA Bacteriano/metabolismo
RNA Mensageiro/metabolismo
Ribonucleases/metabolismo
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Proteínas de Bactérias/metabolismo
Proliferação Celular
Clostridium perfringens/genética
Clostridium perfringens/metabolismo
Colagenase Microbiana/genética
Colagenase Microbiana/metabolismo
RNA Bacteriano/genética
RNA Mensageiro/genética
Ribonucleases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (RNA, Bacterial); 0 (RNA, Messenger); EC 3.1.- (Ribonucleases); EC 3.4.24.3 (Microbial Collagenase); EC 3.4.24.3 (kappa-toxin, Clostridium perfringens)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170715
[Lr] Data última revisão:
170715
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161109
[St] Status:MEDLINE


  6 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27682305
[Au] Autor:Verstreken F; Degreef I; Decramer A; Libberecht K; Vanhove W; Datco A; Vanhaecke J; Clermont D; Duerinckx J
[Ti] Título:Effectiveness and safety of collagenase Clostridium histolyticum in Dupuytren's disease : an observational study in Belgium.
[So] Source:Acta Orthop Belg;82(2):397-404, 2016 Aug.
[Is] ISSN:0001-6462
[Cp] País de publicação:Belgium
[La] Idioma:eng
[Ab] Resumo:Dupuytren's disease is a connective tissue disorder leading to contractures. It can be treated surgically or through injections of collagenase Clostridium histolyticum (CCH). Patients with Dupuytren's contracture (> 20°) and a palpable cord were included in this observational study, aiming to characterise the Belgian patient population and to assess the effectiveness and safety of CCH. Overall, 108 patients (114 joints) received at least one injection of CCH, and 104 patients completed the study. The percentages of joints achieving a degree of contracture of 5° or less, or a relative contracture reduction of at least 50% after the extension procedure were 64.9% and 90.1%, respectively. The mean number of injections per cord was 1.0. The Unité Rhumatologique des Affections de la Main score decreased from 29.4 ±â€ˆ11.0 to 12.9 ±â€ˆ6.3 (mean ±â€ˆSD ; p < 0.0001). CCH was demonstrated to be effective, safe and able to increase quality of life.
[Mh] Termos MeSH primário: Contratura de Dupuytren/tratamento farmacológico
Colagenase Microbiana/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Bélgica
Feminino
Seres Humanos
Injeções Intralesionais
Masculino
Colagenase Microbiana/administração & dosagem
Colagenase Microbiana/efeitos adversos
Meia-Idade
Qualidade de Vida
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170113
[Lr] Data última revisão:
170113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160930
[St] Status:MEDLINE


  7 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27649672
[Au] Autor:Sanjuan-Cervero R; Poquet-Jornet JE; Carrera-Hueso FJ
[Ad] Endereço:Department of Orthopedic Surgery and Traumatology, Hospital de Denia, Denia - Alicante, Spain. sanjuan.rafcer@gmail.com.
[Ti] Título:Toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for Dupuytren´s disease.
[So] Source:Eur Rev Med Pharmacol Sci;20(17):3688-91, 2016 Sep.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Secondary effects and drug reactions relative to collagenase Clostridium histolyticum treatment for Dupuytren's contracture are frequent. In only a few cases these secondary effects are considered serious. The mechanism that produces these effects of production is not well understood. CLINICAL REPORT: We present the case report of a woman with fifth finger interphalangeal joint treatment with generalized skin rash as a complication of collagenase Clostridium histolyticum treatment. DISCUSSION: We discuss treatment, causes and mechanisms of this rare complication from this treatment and review the bibliography about mechanisms for the different types of immunological reactions that may occur after treatment with collagenase Clostridium histolyticum and the possibility of crossed reactions with Clostridiopeptidase A used to treat skin lacerations.
[Mh] Termos MeSH primário: Dermatite/etiologia
Contratura de Dupuytren/tratamento farmacológico
Colagenase Microbiana/efeitos adversos
[Mh] Termos MeSH secundário: Clostridium histolyticum
Feminino
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160922
[St] Status:MEDLINE


  8 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27459729
[Au] Autor:Sheets AR; Demidova-Rice TN; Shi L; Ronfard V; Grover KV; Herman IM
[Ad] Endereço:Graduate Program in Cellular & Molecular Physiology, The Sackler School of Graduate Biomedical Sciences, Tufts University, 136 Harrison Ave, Boston, MA, 02111, United States of America.
[Ti] Título:Identification and Characterization of Novel Matrix-Derived Bioactive Peptides: A Role for Collagenase from Santyl® Ointment in Post-Debridement Wound Healing?
[So] Source:PLoS One;11(7):e0159598, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Debridement, the removal of diseased, nonviable tissue, is critical for clinicians to readily assess wound status and prepare the wound bed for advanced therapeutics or downstream active healing. Removing necrotic slough and eschar through surgical or mechanical methods is less specific and may be painful for patients. Enzymatic debridement agents, such as Clostridial collagenase, selectively and painlessly degrade devitalized tissue. In addition to its debriding activities, highly-purified Clostridial collagenase actively promotes healing, and our past studies reveal that extracellular matrices digested with this enzyme yield peptides that activate cellular migratory, proliferative and angiogenic responses to injury in vitro, and promote wound closure in vivo. Intriguingly, while collagenase Santyl® ointment, a sterile preparation containing Clostridial collagenases and other non-specific proteases, is a well-accepted enzymatic debridement agent, its role as an active healing entity has never been established. Based on our previous studies of pure Clostridial collagenase, we now ask whether the mixture of enzymes contained within Santyl® produces matrix-derived peptides that promote cellular injury responses in vitro and stimulate wound closure in vivo. Here, we identify novel collagen fragments, along with collagen-associated peptides derived from thrombospondin-1, multimerin-1, fibronectin, TGFß-induced protein ig-h3 and tenascin-C, generated from Santyl® collagenase-digested human dermal capillary endothelial and fibroblastic matrices, which increase cell proliferation and angiogenic remodeling in vitro by 50-100% over controls. Using an established model of impaired healing, we further demonstrate a specific dose of collagenase from Santyl® ointment, as well as the newly-identified and chemically-synthesized ECM-derived peptides significantly increase wound re-epithelialization by 60-100% over saline-treated controls. These results not only confirm and extend our earlier studies using purified collagenase- and matrix-derived peptides to stimulate healing in vitro and in vivo, but these Santyl®-generated, matrix-derived peptides may also represent exciting new opportunities for creating advanced wound healing therapies that are enabled by enzymatic debridement and potentially go beyond debridement.
[Mh] Termos MeSH primário: Colagenases/metabolismo
Matriz Extracelular/metabolismo
Peptídeos/metabolismo
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Desbridamento
Fibroblastos/metabolismo
Células Endoteliais da Veia Umbilical Humana/metabolismo
Seres Humanos
Camundongos
Colagenase Microbiana/metabolismo
Modelos Animais
Peptídeos/química
Proteólise
Regeneração
Cicatrização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Peptides); EC 3.4.24.- (Collagenases); EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160727
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0159598


  9 / 5423 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27432377
[Au] Autor:Aliperti LA; Mehta A
[Ad] Endereço:Department of Urology, Emory University School of Medicine, 1365 Clifton Road, NE, Building B, Suite 1400, Atlanta, GA, 30322, USA.
[Ti] Título:Peyronie's Disease: Intralesional Therapy and Surgical Intervention.
[So] Source:Curr Urol Rep;17(9):60, 2016 Sep.
[Is] ISSN:1534-6285
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Peyronie's disease is a collagen wound healing disorder of the penis that negatively affects the quality of life of afflicted men. According to the 2015 AUA Consensus Guidelines on Peyronie's Disease, minimally invasive intralesional therapies and surgical intervention form the basis of contemporary therapy for this disorder. These therapeutic options, along with selected portions of the guidelines, are explored in this review.
[Mh] Termos MeSH primário: Induração Peniana/terapia
[Mh] Termos MeSH secundário: Bloqueadores dos Canais de Cálcio/uso terapêutico
Seres Humanos
Interferon-alfa/uso terapêutico
Masculino
Colagenase Microbiana/uso terapêutico
Proteínas Recombinantes/uso terapêutico
Procedimentos Cirúrgicos Urológicos Masculinos
Verapamil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Interferon-alpha); 0 (Recombinant Proteins); 43K1W2T1M6 (interferon alfa-2b); CJ0O37KU29 (Verapamil); EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160720
[St] Status:MEDLINE
[do] DOI:10.1007/s11934-016-0622-2


  10 / 5423 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27387760
[Au] Autor:Leopold SS
[Ad] Endereço:Clinical Orthopaedics and Related Research, 1600 Spruce Street, Philadelphia, PA, 19013, USA. sleopold@clinorthop.org.
[Ti] Título:Editor's Spotlight/Take 5: CORR ORS Richard A. Brand Award: Clinical Trials of a New Treatment Method for Adhesive Capsulitis.
[So] Source:Clin Orthop Relat Res;474(11):2323-2326, 2016 Nov.
[Is] ISSN:1528-1132
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Bolsa Sinovial/efeitos dos fármacos
Bursite/tratamento farmacológico
Clostridium histolyticum/enzimologia
Colagenase Microbiana/administração & dosagem
Articulação do Ombro/efeitos dos fármacos
Dor de Ombro/tratamento farmacológico
[Mh] Termos MeSH secundário: Distinções e Prêmios
Fenômenos Biomecânicos
Bolsa Sinovial/fisiopatologia
Bursite/diagnóstico
Bursite/fisiopatologia
Seres Humanos
Injeções Intralesionais
Colagenase Microbiana/efeitos adversos
Colagenase Microbiana/isolamento & purificação
Ensaios Clínicos Controlados Aleatórios como Assunto
Recuperação de Função Fisiológica
Articulação do Ombro/fisiopatologia
Dor de Ombro/diagnóstico
Dor de Ombro/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:EDITORIAL; PORTRAITS
[Nm] Nome de substância:
EC 3.4.24.3 (Microbial Collagenase)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160709
[St] Status:MEDLINE



página 1 de 543 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde